im quite interested in the effects.
Modafinil ('Provigil', 'Alertec', 'Vigicer', 'Modalert', etc) is a memory-improving and mood-brightening psychostimulant. It enhances wakefulness, attention capacity and vigilance.
Current research suggests modafinil, like its older and better-tested analogue adrafinil , is a safe, effective and well-tolerated agent. It is long-acting and doesn't tend to cause peripheral sympathetic stimulation. Yet its CNS action isn't fully understood. Modafinil induces wakefulness in part by its action in the anterior hypothalamus. Its dopamine -releasing action in the nucleus accumbens is weak and dose-dependent; the likelihood of a euphoric response ('abuse potential'), dose-escalation and tolerance is thus apparently small. However, antagonism of the dopamine D1 and D2 receptors completely prevents modafinil-induced arousal.
Has anyone here use them before, if so, what kind of dosage? Did you take as described? Ie just shallow tablet or did you use another ROA?
The recommended dose of modafinil is 200 mg given once a day. For patients with narcolepsy and OSAHS, modafinil should be taken as a single dose in the morning. For patients with SWSD, it should be taken approximately 1 hour prior to the start of their work shift.
Doses up to 400 mg/day, given as a single dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.
*i've never tried this drug before (that i am aware of). I would try it, probably...sounds pretty similar to most of the add/adhd meds available.
Is it something that someone could compare to street speed or RC stims? (MPA/EPH etc..)
its pharmacological profile is notably different from the amphetamines , methylphenidate (Ritalin ) or cocaine . Modafinil is less likely to cause jitteriness, anxiety, or excess locomotor activity - or lead to a hypersomnolent 'rebound effect' - than traditional stimulants . Subjectively, it feels smoother and cleaner than the amphetamines too. It may even be anxiolytic.
modafinil is a wakefulness-promoting agent for oral administration. modafinil is a racemic compound. The chemical name for modafinil is:
2-[(diphenylmethyl)sulfinyl]acetamide. The molecular formula is C15H15NO2S and the molecular weight is 273.36.
The precise mechanism(s) through which modafinil promotes wakefulness is unknown. Modafinil has wake-promoting actions like sympathomimetic agents including amphetamine and methylphenidate, although the pharmacologic profile is not identical
to that of sympathomimetic amines.
At pharmacologically relevant concentrations, modafinil does not bind to most potentially relevant receptors for sleep/wake regulation, including those for norepinephrine, serotonin, dopamine, GABA, adenosine, histamine-3, or melatonin.
Modafinil is not a direct- or indirect-acting dopamine receptor agonist and is inactive in several in vivo preclinical models capable of detecting enhanced dopaminergic activity.
In vitro, modafinil binds to the dopamine reuptake site and causes an increase in extracellular dopamine, but no increase in dopamine release. In a preclinical model, the wakefulness induced by amphetamine, but not modafinil, is antagonized by the
dopamine receptor antagonist haloperidol.
USES:
Modafinil is proving clinically useful in the treatment of narcolepsy, a neurological disorder marked by uncontrollable attacks of daytime sleepiness. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins. Orexin neurons are activated by modafinil. Orexinergic neurons are found exclusively in the lateral hypothalamic area. Their activation is associated with enhanced pleasure-seeking and motivation as well as arousal. Orexinergic fibers project to the entire central nervous system. Genetically modified orexin-knockout animals offer a model of human narcolepsy. Narcoleptics suffer profound disturbances in normal sleeping patterns and variable degrees of depression. These symptoms can be reversed with modafinil. Selective orexin receptor agonists of the future may prove useful both to narcoleptics and the population at large.
Experimentally, modafinil is also used in the treatment of Alzheimer's disease; depression; attention-deficit disorder (ADHD); myotonic dystrophy; multiple sclerosis-induced fatigue; post-anaesthesia grogginess; cognitive impairment in schizophrenia; spasticity associated with cerebral palsy, age-related memory decline; idiopathic hypersomnia; methamphetamine ('Ice') abuse; apathy in the elderly; jet-lag; cancer-associated fatigue and opioid-induced sedation; fatigue in Charcot-Marie-Tooth Disease (CMT); Kleine Levin syndrome ('Rip van Winkle' disease); and everyday cat-napping. Skeptics cite the broadly comparable therapeutic equivalance of a cup of coffee.
www.biopsychiatry.com